S. Topalian

S. Rosenberg, M. Nishimura, S. Topalian, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.

S. Rosenberg, S. Topalian, D. Schwartzentruber, 1991, Journal of immunology.

Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.

S. Rosenberg, S. Topalian, D. Schwartzentruber, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells

S. Rosenberg, S. Topalian, R. Hartzman, 1994, International journal of cancer.

Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

K. Sakaguchi, E. Appella, S. Rosenberg, 1995, Journal of immunology.

Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.

S. Rosenberg, S. Topalian, A. Kasid, 1990, Journal of immunology.

Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest

S. Rosenberg, S. Topalian, N. Restifo, 1994, Cancer Immunology, Immunotherapy.

Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.

R. K. Bright, M. Nishimura, S. Topalian, 1999, Journal of immunology.

T Cells + MHC-Restricted CD8 Cancer-Associated Antigen by Nonclassical Recognition of a Shared Human Prostate

R. K. Bright, S. Topalian, F. Housseau, 1999 .

Melanoma and immunotherapy bridge 2015 K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR in melanoma

L. Cope, J. Taube, Jinshui Fan, 2016 .

Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2.

W. Linehan, P. Hwu, J. Mulé, 1992, Human gene therapy.

Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor.

A. Asher, W. Linehan, P. Hwu, 1992, Human gene therapy.

Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.

A. Belldegrun, S. Rosenberg, M. Lotze, 1989, Journal of immunology.

Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer

A. Belldegrun, S. Rosenberg, S. Topalian, 1987 .

Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion

S. Rosenberg, S. Topalian, S. S. Hom, 2005, Cancer Immunology, Immunotherapy.

Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes.

S. Rosenberg, S. Topalian, N. Markus, 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

F. Marincola, S. Rosenberg, J. Yang, 1995, Cancer.

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

S. Steinberg, S. Topalian, D. White, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of intravenous interleukin-6 in patients with advanced cancer.

S. Rosenberg, S. Topalian, D. Parkinson, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.

S. Rosenberg, M. Lotze, B. Pockaj, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer

S. Steinberg, M. Merino, S. Rosenberg, 2003 .

a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the

F. Marincola, S. Rosenberg, P. Hwu, 1999 .

Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.

G. Rosner, V. Velculescu, J. Wolchok, 2016 .

Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary SyndromesRao SV, Jollis JG, Harrington RA, et al (Duke Univ, Durham, NC; Univ of Alberta, Edmonton, Canada; Univ of Kentucky, Lexington; et al) JAMA 292:1555–1562, 2004§

C. Bekes, Aseem Kumar, S. Topalian, 2006 .

A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin‐2 Therapy

S. Steinberg, S. Rosenberg, M. Lotze, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

S. Rosenberg, I. Lowy, J. Yang, 2010, Journal of immunotherapy.

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

S. Steinberg, F. Marincola, S. Rosenberg, 1996, The cancer journal from Scientific American.

Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies

J. Taube, E. Lipson, Lieping Chen, 2012 .

Balance and imbalance in the immune system: life on the edge.

A. Sharpe, S. Topalian, 2014, Immunity.

Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial InfarctionHochman JS, for the SHOCK Investigators (New York Univ; et al) JAMA 295:2511–2515, 2006§

C. Bekes, S. Topalian, 2007 .

Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.

S. Steinberg, S. Topalian, D. White, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.

S. Rosenberg, S. Topalian, M. Stetler-Stevenson, 1993, Blood.

Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses.

S. Steinberg, S. Rosenberg, B. Pockaj, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

G. Haas, W. Linehan, M. Walther, 1992, The Journal of urology.

Selection of optimal therapy for neuroblastoma: A Study of the Immunomodulatory Effects of Surgery and Irradiation in the Murine C1300 Neuroblastoma Model

S. Topalian, M. Ziegler, Suzanne L. Topalian, 1987, Journal of surgical oncology.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

necrosis factor-alpha in response to autologous tumor stimulation secrete granulocyte-macrophage colony-stimulating factor and tumor Tumor-infiltrating lymphocytes derived from select B-cell lymphomas

S. Topalian, M. Stetler-Stevenson, D. Schwartzentruber, 2011 .

Immunotherapy: The Path to Win the War on Cancer?

J. Banchereau, J. Wolchok, T. Chan, 2015, Cell.

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

H. Kohrt, E. Lipson, H. Kluger, 2015 .

Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.

David R. Jones, V. Rusch, V. Velculescu, 2017 .

Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes

S. Rosenberg, S. Topalian, D. Schwartzentruber, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

F. Marincola, J. Galon, S. Demaria, 2016, Journal of Immunotherapy for Cancer.

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

S. Rosenberg, J. Yang, S. Topalian, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks.

S. Rosenberg, S. Topalian, T. Okarma, 1990, Journal of biological response modifiers.

Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

A. Belldegrun, S. Rosenberg, S. Topalian, 1989, Journal of immunology.

Enterocolitis in Patients After Antibody Blockade of CTLA-4.

S. Rosenberg, J. Yang, S. Topalian, 2005 .

The Development of Gene Therapy for the Treatment of Cancer

S. Rosenberg, W. Anderson, P. Hwu, 1993, Annals of surgery.

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

G. Semenza, K. Zeller, C. Dang, 2011, Cell.

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2014 .

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor.

S. Topalian, Y. Skornick, S. Rosenberg, 1990, Journal of Biological Response Modifiers.

Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study.

M. Sanda, M. Lotze, S. Topalian, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

D. Schadendorf, U. Martens, S. Topalian, 2017 .

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy

Toby C. Cornish, J. Taube, E. Lipson, 2017, JAMA oncology.

Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma.

J. Taube, Jinshui Fan, C. Cheadle, 2013 .

Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Thomas A. Davis, Steven A. Rosenberg, Douglas J. Schwartzentruber, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

J. Taube, A. Klein, Lieping Chen, 2014, Clinical Cancer Research.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

J. Taube, E. Lipson, L. Emens, 2015, Seminars in oncology.

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.

J. Taube, C. Drake, Lieping Chen, 2013, Cancer research.

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

John Mao, Francesco M Marincola, F. Marincola, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant checkpoint blockade for cancer immunotherapy

J. Taube, D. Pardoll, S. Topalian, 2020, Science.

Alterations of immune response of non-small cell lung cancer with Azacytidine

Peter A. Jones, C. Zahnow, P. Laird, 2013, Oncotarget.

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

S. Steinberg, F. Marincola, S. Rosenberg, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

S. Steinberg, W. Linehan, A. Chang, 1993, Journal of the National Cancer Institute.

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

C. Drake, D. Pardoll, S. Topalian, 2012, Current opinion in immunology.

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

J. Taube, C. Drake, E. Lipson, 2012, Clinical Cancer Research.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Drew M. Pardoll, Janis M. Taube, Paul T. Nghiem, 2016, The New England journal of medicine.

The role of CD4+ T cell responses in antitumor immunity.

D. Pardoll, S. Topalian, 1998, Current opinion in immunology.

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

D. Schadendorf, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

F. Marincola, S. Rosenberg, P. Hwu, 1998, Journal of the National Cancer Institute.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Ludmila V. Danilova, J. Taube, E. Lipson, 2018, Journal of Immunotherapy for Cancer.

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.

J. Sidney, A. Sette, D. Hunt, 2010, Journal of molecular biology.

Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells

J. Shabanowitz, D. Hunt, G. Gupta, 1999, The Journal of experimental medicine.

Abstract 662: The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC)

Haiying Xu, Candice D. Church, Janis M. Taube, 2017 .

Cancer immunotherapy comes of age.

Drew M Pardoll, D. Pardoll, S. Topalian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

S. Rosenberg, S. Topalian, R. Wang, 1999, Science.

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Ludmila V. Danilova, A. Szalay, L. Cope, 2021, Science.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy

H. Kluger, S. Topalian, P. Nghiem, 2018, Journal of Immunotherapy for Cancer.

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Alexander V. Favorov, L. Cope, B. Taylor, 2017, Clinical Cancer Research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

K 3 Tumor ‐ intrinsic beta ‐ catenin signaling mediates tumor ‐ immune avoidance

L. Cope, J. Taube, Jinshui Fan, 2016 .

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

S. Rosenberg, J. Yang, S. Topalian, 1994, JAMA.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens.

R. K. Bright, W. M. Linehan, M. Emmert-Buck, 1997, Cancer research.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

Necrotizing enterocolitis: a review of animal models.

S. Topalian, M. Ziegler, Moritz M. Ziegler, 1984, The Journal of surgical research.

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

J. Taube, C. Chung, S. Chiosea, 2021, Journal for ImmunoTherapy of Cancer.

Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression.

R. Morgan, G. Lizée, J. Aerts, 2003, Human gene therapy.

NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer

G. Rosner, V. Velculescu, J. Taube, 2016 .

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

J. Taube, S. Broderick, P. Illei, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

David R. Jones, G. Rosner, M. Brock, 2020, Journal for ImmunoTherapy of Cancer.

The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas

N. Socci, B. Taylor, C. Iacobuzio-Donahue, 2020, Clinical Cancer Research.

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Ludmila V. Danilova, L. Cope, J. Taube, 2016, Cancer Immunology Research.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

J. Taube, D. Pardoll, A. Meeker, 2017, Blood advances.

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Ludmila V. Danilova, J. Taube, S. Signoretti, 2023, Cell reports. Medicine.

Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.

J. Taube, M. Oberley, R. Herbst, 2022, JCO precision oncology.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

S. Steinberg, M. Merino, S. Rosenberg, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.

S. Rosenberg, S. Topalian, R. Wang, 1998, Journal of immunology.

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

W. Linehan, A. Chang, M. Lotze, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial designs for the early clinical development of therapeutic cancer vaccines.

S. Steinberg, J. Berzofsky, R. Simon, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.

J. Taube, C. Chung, R. Ferris, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Science Journals — AAAS

J. Taube, D. Pardoll, S. Topalian, 2020 .

PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival

Luciane T. Kagohara, J. Taube, E. Lipson, 2013, Cancer Immunology Research.

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).

J. Sosman, F. Hodi, M. Sznol, 2012 .

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

P. Hwu, J. Wigginton, A. Gupta, 2012 .

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

A Sette, A. Sette, S. Rosenberg, 1996, The Journal of experimental medicine.

Structural basis for the recognition of mutant self by a tumor-specific, MHC class II–restricted T cell receptor

M. Nishimura, R. Mariuzza, P. Brown, 2007, Nature Immunology.

Structural insights into the editing of germ-line–encoded interactions between T-cell receptor and MHC class II by Vα CDR3

R. Mariuzza, S. Topalian, R. Langley, 2012, Proceedings of the National Academy of Sciences.

Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.

J. Taube, C. Chung, R. Ferris, 2018 .

520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358

S. Topalian, W. Sharfman, V. Boni, 2022, Annals of Oncology.

Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

C. Chung, Y. Bang, T. Meyer, 2019, Annals of Oncology.

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

J. Machiels, T. Meyer, S. Topalian, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

S. Rosenberg, J. Yang, A. Maker, 2006, Journal of immunotherapy.

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

Steven P Rowe, Amanda Blackford, Alin Chirindel, 2017, The Journal of Nuclear Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

S. Rosenberg, S. Topalian, L. Muul, 1987, Journal of immunological methods.

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop

D. Berry, J. Taube, K. Flaherty, 2020, Clinical Cancer Research.

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Vanessa M. Hubbard-Lucey, J. Taube, R. Sullivan, 2020, Journal for ImmunoTherapy of Cancer.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.

D. Schadendorf, J. Larkin, M. Sznol, 2015 .

In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

S. Steinberg, S. Rosenberg, S. Topalian, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

S. Steinberg, S. Rosenberg, M. Gonzales, 2006, Clinical Cancer Research.

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

J. Taube, E. Lipson, D. Pardoll, 2015, Journal of Translational Medicine.

Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice

Steven A. Rosenberg, S. Rosenberg, S. Topalian, 2000, The Journal of Immunology.

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

F. Marincola, S. Rosenberg, P. Hwu, 1999, Journal of immunology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.

S. Topalian, S L Topalian, 1994, Current opinion in immunology.

Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

C. Drake, I. Lowy, A. Korman, 2008 .

Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

David C. Smith, R. Motzer, T. Choueiri, 2016 .

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

Drew M Pardoll, V. Velculescu, L. Diaz, 2014, Journal of Immunotherapy for Cancer.

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

Jie Qian, J. Shabanowitz, D. Hunt, 2009, Proceedings of the National Academy of Sciences.

Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity

Suzanne, J. Sidney, A. Sette, 2013, The Journal of Immunology.

Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma

Steven A. Rosenberg, Douglas J. Schwartzentruber, S. Rosenberg, 2003, Journal of immunotherapy.

Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.

J. Shabanowitz, D. Hunt, V. Engelhard, 2017, Journal of proteome research.

Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines

S. Rosenberg, J. Yang, S. Topalian, 2006, Journal of immunotherapy.

PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation

J. Taube, J. Eshleman, Ming-Tseh Lin, 2014, Cancer Immunology Research.

Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients.

F. Marincola, S. Topalian, D. Parkinson, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Microenvironment and Immunology Evidence for a Role of the PD-1 : PD-L 1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

J. Taube, C. Drake, Lieping Chen, 2013 .

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

J. Machiels, T. Meyer, S. Topalian, 2017 .

365 days: Nature's 10

S. Topalian, 2014, Nature.

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

J. Taube, C. Drake, Lieping Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

First Tissue-Agnostic Drug Approval Issued.

J. Wolchok, D. Rimm, S. Topalian, 2017, Cancer discovery.

Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.

C. Drake, I. Lowy, A. Korman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular immunotherapy of cancer

S. Rosenberg, S. Topalian, S A Rosenberg, 1990, Critical care medicine.

Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.

R. Scharpf, V. Velculescu, J. Taube, 2020 .

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

Meeting report: The future of preclinical mouse models in melanoma treatment is now

K. Flaherty, M. Herlyn, G. Merlino, 2013, Pigment cell & melanoma research.

Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy.

Peter A. Jones, C. Zahnow, S. Baylin, 2013 .

Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma

F. Marincola, S. Rosenberg, P. Hwu, 2002 .

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Appendix: Supplemental Figures

Peter A. Jones, C. Zahnow, P. Laird, 2020, Deserter Country.

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of immunotherapy.

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.

D. Pardoll, L. Emens, S. Topalian, 2023, Cancer cell.

Selection of optimal therapy for neuroblastoma: A Study of the Immunomodulatory Effects of Surgery and Irradiation in the Murine C1300 Neuroblastoma Model

S. Topalian, M. Ziegler, 1987, Journal of Surgical Oncology.

Heterogeneous Immunogenicity Restricted Peptide Ligands with - Class II Structure-Based Design of Altered MHC

J. Sidney, A. Sette, J. Shabanowitz, 2014 .

Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor G4

R. Mariuzza, S. Topalian, R. Langley, 2012 .

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

J. Taube, C. Drake, Lieping Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

C. Drake, D. Pardoll, S. Topalian, 2012, Current opinion in immunology.

Immune checkpoint blockade: a common denominator approach to cancer therapy.

C. Drake, D. Pardoll, S. Topalian, 2015, Cancer cell.

An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).

J. Machiels, R. Ferris, S. Topalian, 2017 .

Alterations of immune response of non-small cell lung cancer with Azacytidine

C. Zahnow, D. Weisenberger, S. Baylin, 2013, Oncotarget.

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Alexander V. Favorov, L. Cope, B. Taylor, 2017, Clinical Cancer Research.

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

A. Sette, S. Rosenberg, S. Topalian, 1996, The Journal of experimental medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

S. Topalian, M. Stetler-Stevenson, D. Schwartzentruber, 1993, Blood.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

J. Taube, D. Pardoll, A. Meeker, 2017, Blood advances.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

J. Taube, T. Olencki, E. Lipson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade

J. Taube, E. Lipson, D. Pardoll, 2024, Journal of translational medicine.

Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma

D. Pardoll, S. Topalian, D. Koelle, 2024, Cell reports. Medicine.

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.

S. Topalian, W. Sharfman, L. Devriese, 2024, The Lancet Oncology.

T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma

A. Bentzen, S. Hadrup, S. Topalian, 2024, The Journal of clinical investigation.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

J. Taube, J. Sosman, F. Hodi, 2013 .

PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation

J. Taube, J. Eshleman, Ming-Tseh Lin, 2014, Cancer Immunology Research.

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.